Spine Journal - 2026-10-18 - Journal Article
Comparison of Lateral Decubitus versus Prone Lateral Lumbar Interbody Fusion Using Impact Scores: A Method to Quantify Intraoperative Supply Cost and Variability in Surgery.
Lala E, Nguyen K, Yamanouchi K, de Oliveira RG, Ali MA, Younus I, Nemani VM, Leveque JC, Louie PK, Bansal A
Topics
Key Takeaway
Total intraoperative cost did not differ between LD-LIF and PL-LIF ($16,404 vs $17,206, p=0.462), but impact score analysis revealed biologic cost share varied more than two-fold across three surgeons (median ~5% to ~19%), identifying biologics as the dominant modifiable cost driver invisible to aggregate cost metrics.
Summary Depth
Choose how much analysis to show on this article page.
Summary
This study introduced the 'Impact Score'—each supply category's percentage share of total intraoperative cost—as a cost-distribution framework, validated using single-level L4-5 LD-LIF versus PL-LIF cases at a single tertiary center. Impact scores differed significantly by approach for interbody, screw, biologic, and retractor/dilator categories (LD-LIF higher) and neuromonitoring and positioning (PL-LIF higher), while navigation and rod did not differ. Total intraoperative cost, staff cost, and exploratory ODI- and PROMIS-10-derived value metrics showed no significant between-approach difference, yet impact scoring localized inter-surgeon biologic variability exceeding two-fold that aggregate metrics obscured.
Key Limitation
Three-surgeon, single-center design with no vendor pricing standardization means impact score distributions are institution-specific and cannot be benchmarked externally without multicenter validation.
Original Abstract
BACKGROUND CONTEXT
Surgical value metrics report intraoperative supply costs as aggregate institutional dollars, which do not identify which supply categories drive cost.
PURPOSE
To introduce the Impact Score, each supply category's percentage share of total intraoperative supply cost, as a descriptive framework and, using lateral decubitus (LD-LIF) versus prone lateral (PL-LIF) lateral lumbar interbody fusion as a proof of concept, to determine whether impact scores differ by supply category and align with median-cost rankings, whether exploratory outcome-based value metrics differ between approaches, and whether meaningful inter-surgeon variability exists.
STUDY DESIGN/SETTING
Retrospective single-center cohort study at a tertiary center.
PATIENT SAMPLE
Seventy-eight single-level L4-5 lateral lumbar interbody fusion cases performed from 2021 to 2026 (32 LD-LIF, 46 PL-LIF).
OUTCOME MEASURES
Category-level impact score (percentage of total intraoperative supply cost), supply and total intraoperative cost, exploratory value metrics based on the Oswestry Disability Index and PROMIS-10-derived quality-adjusted life years (including the operative value index and unit price per outcome), and 90-day readmission.
METHODS
Itemized intraoperative supply records were mapped to 33 standardized categories, and each category's impact score was computed as its percentage of total intraoperative supply cost. Time-driven activity-based costing provided staff costs. Category-level impact scores and costs were compared with unadjusted Wilcoxon rank-sum tests.
RESULTS
Impact-score and median-cost rankings were broadly concordant. LD-LIF showed higher impact for interbody, screw, biologic, and retractor/dilator, and PL-LIF for neuromonitoring and positioning (all p < 0.01). Navigation and rod did not differ. Total intraoperative cost did not differ between approaches (PL-LIF $17,206 vs LD-LIF $16,404, p = 0.462), nor did staff cost (p = 0.607), and exploratory value metrics did not establish a cost-effectiveness difference, whereas the impact score localized the between-approach difference to supply composition. Biologic impact varied most, with a more than two-fold range among the three surgeons (median approximately 5% to 19%) and higher biologic impact in LD-LIF within individual surgeons.
CONCLUSIONS
The impact score describes how intraoperative supply costs are distributed across categories. In this single-center, three-surgeon cohort, it identified a potentially modifiable cost driver that neither total cost nor exploratory value metrics revealed. Its use for cross-institutional benchmarking will require a multicenter study of how impact scores vary between institutions with differing vendor pricing and contracting. Because it reflects only the intraoperative phase, it complements, rather than replaces, episode-of-care and outcome-based value assessment.
LEVEL OF EVIDENCE
Level III, retrospective comparative study.